Detection and Diagnosis of Pancreatic Cancer

胰腺癌的检测和诊断

• 批准号: 7459750
• 负责人: DAVID V GOLD
• 金额: $ 24.14万
• 依托单位: CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-09 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7459750
• 关键词: Affinity; Antibodies; Antigens; Attention; Benign; Binding Sites; Biological; Biological Assay; Biological Markers; Breast; Carbohydrates; Cessation of life; Characteristics; Colon; Colorectal; Colorectal Cancer; Detection; Diagnosis; Diagnostic Procedure; Discrimination; Disease; Disease Management; Early Diagnosis; Enzyme Immunoassay; Epitopes; Evaluation; Genus Cola; Glycoside Hydrolases; Heterogeneity; Immunoassay; In Vitro; Liquid substance; Location; Lung; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of pancreas; Mind; Molecular; Molecular Profiling; Monoclonal Antibodies; Mucin-1 Staining Method; Mucin-2 Staining Method; Mucins; Multivariate Analysis; Nature; Oligosaccharides; Organ; Ovary; Pancreas; Pancreatic Diseases; Pancreatitis; Patients; Pattern; Peptides; Population; Post-Translational Protein Processing; Process; Progress Review Group; Prostate; Recommendation; Reporting; Reproducibility; Screening procedure; Sensitivity and Specificity; Specificity; Specimen; Staging; Standards of Weights and Measures; Structure; Study Section; Survival Rate; Technology; Time; Tissues; Translating; Woman; antigen binding; base; cancer type; carbohydrate structure; design; diagnostic accuracy; glycosyltransferase; immunoreactivity; improved; malignant breast neoplasm; men; mucin core protein; ovarian neoplasm; pancreatic neoplasm; peptide structure; polyclonal antibody; protein aminoacid sequence; tumor; tumor growth

DESCRIPTION (provided by applicant): Pancreatic cancer is one of the most insidious forms of cancer. Recent estimates of new cancer cases put pancreatic cancer at eighth and ninth among women and men, respectively. However, it is the fourth leading cause of all cancer deaths in both women and men, surpassed only by lung, colorectal, prostate, and breast cancers. Due largely to the location, and silent growth of the tumor, most patients present at a time when it is too late to undergo any realistic type of curative treatment. This has translated into a 5-year survival rate of less than 3%. In a recent report, "Pancreatic Cancer: An Agenda for Action", the NCI's Pancreatic cancer Progress Review Group drew specific attention to the urgent need for "better screening and diagnostic techniques" with a recommendation to "delineate and validate effective molecular biomarkers" for pancreatic cancer. With this in mind, we intend to develop and assess the utility of a PAM4, anti-MUC1 antibody-based immunoassay to detect, diagnose, and provide for the management of this disease. Although there have been several reports concerning anti-MUC1 MAbs reactive with several types of cancer, PAM4 appears to be unique, or nearly so, in terms of its specificity and the molecular characteristics of the epitope to which it is reactive. The long-term objective of this proposal is to identify specific biomarkers that can be combined with the PAM4 assay for enhanced diagnostic accuracy of pancreatic cancer. The specific aims of this proposal are Aim 1. To investigate the diagnostic accuracy of an immunoassay for the quantitation of PAM4-reactive MUC1 in biological fluids as a means for early detection and diagnosis of pancreatic cancer. Aim 2. To investigate the heterogeneity in expression of MUC1 epitope structures as a means to identify patterns that may be organ and/or tumor "specific/associated". Aim 3. To investigate whether inclusion of other mucin biomarkers can increase diagnostic accuracy through multivariate analyses.

描述（由申请人提供）：胰腺癌是最隐蔽的癌症形式之一。最近对新癌症病例的估计将胰腺癌在女性和男性中分别排在第八位和第九位。然而，它是女性和男性所有癌症死亡的第四大原因，仅次于肺癌，结肠直肠癌，前列腺癌和乳腺癌。主要由于肿瘤的位置和无声生长，大多数患者出现在接受任何现实类型的治愈性治疗时已经太晚了。这意味着5年生存率不到3%。在最近的一份报告中，“胰腺癌：行动议程”，NCI的胰腺癌进展审查小组提请特别注意迫切需要“更好的筛查和诊断技术”，并建议“描绘和验证有效的分子生物标志物”胰腺癌。考虑到这一点，我们打算开发和评估PAM 4，抗MUC 1抗体为基础的免疫测定检测，诊断，并提供这种疾病的管理的效用。尽管已经有几个关于与几种类型的癌症反应的抗MUC 1单克隆抗体的报道，但PAM 4在其特异性和与其反应的表位的分子特征方面似乎是独特的，或几乎如此。该提案的长期目标是确定可以与PAM 4检测相结合的特定生物标志物，以提高胰腺癌的诊断准确性。本提案的具体目标是目标1。研究生物体液中PAM 4反应性MUC 1定量免疫测定的诊断准确性，作为胰腺癌早期检测和诊断的一种手段。 目标2.研究MUC 1表位结构表达的异质性，以鉴定可能是器官和/或肿瘤“特异性/相关”的模式。目标3.通过多变量分析，研究纳入其他粘蛋白生物标志物是否可以提高诊断准确性。